Keywords: ضد Xa; Enoxaparin; Anti-Xa; Venous thromboembolism;
مقالات ISI ضد Xa (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ضد Xa; Anaphylaxis; mast cell; bradykinin; mouse models; tryptase; contact system; ACE; Angiotensin-converting enzyme; Anti-Xa; Anti-factor Xa activity; aPTT; Activated partial thromboplastin time; Bdkrb1; B1R coding gene; Bdkrb2; B2R coding gene; B1R; Bradyki
Assessment of Heparin Anticoagulation Measured Using i-STAT and Hemochron Activated Clotting Time
Keywords: ضد Xa; anticoagulation; heparin; activated clotting time; anti-Xa; i-STAT;
Partial thromboplastin time is more predictive of bleeding than anti-Xa levels in heparinized pediatric patients after cardiac surgery
Keywords: ضد Xa; anticoagulation; heparin; bleeding; thrombosis; congenital heart disease; Anti-Xa; anti-factor Xa activity; aPTT; activated partial thromboplastin time; ATIII; antithrombin III; CI; confidence interval; CICU; cardiac intensive care unit; IQR; interquartil
Should we abandon the APTT for monitoring unfractionated heparin?
Keywords: ضد Xa; Heparin; Activated partial thromboplastin time; Anti-Xa; Concordance; Fibrinogen;
Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?
Keywords: ضد Xa; Direct oral anticoagulants; Anti-Xa; Laboratory; Low-molecular weight heparin; Rivaroxaban;
Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis
Keywords: ضد Xa; Anti-Xa; Low molecular weight heparin; Nadroparin; Nocturnal hemodialysis
Peri-procedural management of dabigatran and rivaroxaban: Duration of anticoagulant discontinuation and drug concentrations
Keywords: ضد Xa; Anticoagulant; Anti-IIa; Anti-Xa; PT; aPTT; Surgery;
A heparin-like glycosaminoglycan from shrimp containing high levels of 3-O-sulfated d-glucosamine groups in an unusual trisaccharide sequence
Keywords: ضد Xa; Heparin; Crustacean; NMR; Anticoagulant activity; Anti-Xa; Antithrombin
Ultrasonic-assisted preparation of a low molecular weight heparin (LMWH) with anticoagulant activity
Keywords: ضد Xa; LMWH; low molecular weight heparin; HIT; heparin-induced thrombocytopenia; GAGs; glycosaminoglycans; UFH; unfractionated heparin; MWavg; average molecular weight; ULMWH; ultra-low-molecular-weight heparin; SEC; size exclusion chromatography; Mn; number-av
Prise en charge des complications hémorragiques graves et de la chirurgie en urgence chez les patients recevant un anticoagulant oral anti-IIa ou anti-Xa direct. Propositions du Groupe d’intérêt en Hémostase Périopératoire (GIHP) - mars 2013
Keywords: ضد Xa; Chirurgie; Hémorragie; Anticoagulants oraux; Anti-IIa; Anti-Xa; Urgence; RéversionSurgery; Haemorrhage; Oral anticoagulant; Anti-IIa; Anti-Xa; Emergency; Reversal
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013
Keywords: ضد Xa; Surgery; Bleeding; Anti-IIa; Anti-Xa; ReversalChirurgie; Hémorragie; Anti-IIa; Anti-Xa; RéversionaPPT, Activated partial thromboplastin time; CkrCl, Creatinine clearance calculated according to the formula of Cockcroft and Gault; FEIBA, Activated prothrom
Tinzaparin Versus Dalteparin for Periprocedure Prophylaxis of Thromboembolic Events in Hemodialysis Patients: A Randomized Trial
Keywords: ضد Xa; Low-molecular-weight heparin; dialysis; anti-Xa; warfarin; invasive procedure;
Fondaparinux - data on efficacy and safety in special situations
Keywords: ضد Xa; ACS; acute coronary syndrome; anti-Xa; anti-factor Xa activity; APS; antiphospholipid syndrome; BID; twice a day; BMI; body mass index; DVT; deep vein thrombosis; EMA; European Medicines Agency; FDA; U.S. Food and Drug Administration; FEIBA; factor eight
Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients
Keywords: ضد Xa; Enoxaparin; Anti-Xa; Pharmacokinetic; Critical care;
Deux nouveaux anticoagulants disponibles en 2010 - Dabigatran Etexilate et Rivaroxaban: progrès attendus - problèmes posés
Keywords: ضد Xa; Dabigatran; Rivaroxaban; Fondaparinux; Anti-Xa; Anti-IIa; Nouveaux anticoagulants; Dabigatran; Rivaroxaban; Fondaparinux; Anti-Xa; Anti-IIa; New anticoagulants;
In vivo age dependency of unfractionated heparin in infants and children
Keywords: ضد Xa; UFH, Unfractionated Heparin; ETP, Endogenous Thrombin Potential; AT, Antithrombin; APTT, Activated Partial Thromboplastin TimeUnfractionated Heparin; Children; Anti-Xa; ETP; APTT
Assessment and management of high-risk pregnancies in women with thrombophilia
Keywords: ضد Xa; Thrombophilia; LMWH; Anti-Xa; Pregnancy complications; Pregnancy loss; Gestational vascular complications
Pharmacodynamics of Unfractionated Heparin During and After a Hemodialysis Session
Keywords: ضد Xa; Anticoagulation; anti-Xa; heparin; hemodialysis; population pharmacokinetics; nonlinear mixed effects modeling (NONMEM);
Thrombelastography monitoring of resistance to enoxaparin anticoagulation in thrombophilic pregnancy patients
Keywords: ضد Xa; Thrombophilic; Pregnancy; Low molecular weight heparin; Anti-Xa;Recurrent pregnancy loss
Monitoring Unfractionated Heparin (UFH) therapy: Which Anti Factor Xa assay is appropriate?
Keywords: ضد Xa; Unfractionated Heparin (UFH), Anti Factor Xa (Anti-Xa).Unfractionated Heparin; Anti-Xa; Children
Increased plasma anti-Xa activity and recovery of heparin from urine suggest absorption of orally administered unfractionated heparin in human subjects
Keywords: ضد Xa; anti-Xa; anti factor Xa; APTT; activated partial thromboplastin time; SNAC; sodium N-[8(-2-hydroxybenzoyl)amino] caprylate; TFPI; tissue factor pathway inhibitor;
Dosage of enoxaparin among obese and renal impairment patients
Keywords: ضد Xa; Anti-Xa; anti-factor Xa activity; BMI; body mass index; CrCl; creatinine clearance; LMWH; low-molecular-weight heparins; S.D.; standard deviation; Low-molecular-weight heparin; Impaired renal function; Obesity; Anticoagulant; Anti-Xa activity;